Pacific Biosciences of California Inc. [PACB] Stock trading around $4.86 per share: What’s Next?

Pacific Biosciences of California Inc. [NASDAQ: PACB] traded at a low on 06/28/22, posting a -8.47 loss after which it closed the day’ session at $4.86. The company report on June 27, 2022 that PacBio Grants Equity Incentive Award to New Employee.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on June 21, 2022.

The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of PacBio as an inducement material to such individual’s entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).

The results of the trading session contributed to over 5930948 shares changing hands. Over the past one week, the price volatility of Pacific Biosciences of California Inc. stands at 11.08% while the volatility over the past one month is 9.77%.

The market cap for PACB stock reached $1.06 billion, with 222.29 million shares outstanding and 204.82 million shares in the current float. Compared to the average trading volume of 7.28M shares, PACB reached a trading volume of 5930948 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Pacific Biosciences of California Inc. [PACB]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $15.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 21, 2022. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on January 06, 2022, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $30, while Cowen analysts kept a Market Perform rating on PACB stock.

The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.49, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 7.88. The Price to Book ratio for the last quarter was 1.47, with the Price to Cash per share for the same quarter was set at 4.41.

How has PACB stock performed recently?

Pacific Biosciences of California Inc. [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.42. With this latest performance, PACB shares dropped by -10.17% in over the last four-week period, additionally sinking by -76.59% over the last 6 months – not to mention a drop of -86.25% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 46.58, with the RSI for the last a single of trading hit 48.42, and the three-weeks RSI is set at 44.61 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 5.61, while it was recorded at 5.22 for the last single week of trading, and 15.02 for the last 200 days.

Pacific Biosciences of California Inc. [PACB]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -136.51 and a Gross Margin at +45.04. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at -138.85.

Return on Equity for this stock declined to -32.18, with Return on Assets sitting at -14.97.

Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.40 and a Current Ratio set at 16.90.

Earnings analysis for Pacific Biosciences of California Inc. [PACB]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.

Insider trade positions for Pacific Biosciences of California Inc. [PACB]

There are presently around $1,193 million, or 95.40% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 27,259,521, which is approximately 3.322% of the company’s market cap and around 0.70% of the total institutional ownership; JACKSON SQUARE PARTNERS, LLC, holding 22,542,589 shares of the stock with an approximate value of $119.7 million in PACB stocks shares; and VANGUARD GROUP INC, currently with $105.91 million in PACB stock with ownership of nearly 0.454% of the company’s market capitalization.

Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 138 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 42,366,902 shares. Additionally, 117 investors decreased positions by around 23,542,639 shares, while 40 investors held positions by with 158,717,710 shares. The mentioned changes placed institutional holdings at 224,627,251 shares, according to the latest SEC report filing. PACB stock had 44 new institutional investments in for a total of 8,075,941 shares, while 49 institutional investors sold positions of 8,103,161 shares during the same period.


Please enter your comment!
Please enter your name here